Sickle Cell Disease (SCD) Decision Aid

• ClinicalTrials.gov Identifier: NCT03224429
• Recruitment Status: Completed
• First Posted: July 21, 2017
• Last Update Posted: June 15, 2018
• Sponsor: Emory University
• Collaborator: Patient-Centered Outcomes Research Institute
• Information provided by (Responsible Party): Lakshmanan Krishnamurti, Emory University

Tracking Information

• First Submitted Date: July 18, 2017
• First Posted Date: July 21, 2017
• Last Update Posted Date: June 15, 2018
• Actual Study Start Date: May 15, 2014
• Actual Primary Completion Date: March 31, 2015 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: July 18, 2017)

• Patient/Caregiver Knowledge of Treatment Risks [ Time Frame: Up to 90 Minutes ]
  Patient and caregiver knowledge of treatment risks will be collected via an open-ended semi- structured interview and aggregated as qualitative data to identify common knowledge gaps.
• Patient/Caregiver Knowledge of Treatment Benefits [ Time Frame: Up to 90 Minutes ]
  Patient and caregiver knowledge of treatment benefits will be collected via an open-ended semi- structured interview and aggregated as qualitative data to identify common knowledge gaps.
• Patient/Caregiver Treatment Expectations [ Time Frame: Up to 90 Minutes ]
  Patient and caregiver treatment expectations will be collected via an open-ended semi- structured interview and aggregated as qualitative data to identify common knowledge gaps.
• Barriers to Understanding Treatment Options [ Time Frame: Up to 90 Minutes ]
  Patient and caregiver knowledge of treatment options will be collected via an open-ended semi- structured interview and aggregated as qualitative data to identify common knowledge gaps.

• Original Primary Outcome Measures: Same as current
• Current Secondary Outcome Measures: Not Provided
• Original Secondary Outcome Measures: Not Provided
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Sickle Cell Disease (SCD) Decision Aid
• Official Title: Comparative Effectiveness of a Decision Aid for Therapeutic Options in Sickle Cell Disease

Brief Summary

The purpose of this study is to gather decision making needs information from caregivers and patients with sickle cell disease (SCD) in order to develop a web-based decision aid tool. Study subjects will participate in interviews defining treatment decision making needs during which investigators will ask information about their SCD. Notes taken from these interviews will allow the research team to better understand current practice related to clinical practice and allow for better refinement of the decision aid tool.

An additional group of participants will be asked to review the web-based Sickle Cell Decision Aid. Participants will be asked to describe thoughts about the site, including but not limited to ease of navigation, content and construction.

This study will provide information for the conduct of a randomized controlled trial for the use of a web based decision aid to give patients with sickle cell disease and parent/legal guardian of children with sickle cell disease accurate information about risks and benefits of therapies and enable them to make decisions based on their individual values and preferences.

Detailed Description

The purpose of this study is to understand patient, family and caregiver needs when making a decision about treatment for their sickle cell disease (SCD). Investigators are developing a decision aid tool that can help people understand SCD treatment options.

One group of subjects will participate in qualitative interviews defining treatment decision making needs during which investigators will ask information about their SCD. Investigators will also discuss treatment choices: hydroxyurea, chronic or monthly blood transfusions and bone marrow transplantation. Participants will be asked their thoughts about how to develop a web-based decision aid tool. Notes taken from these interviews will allow the research team to better understand current practice related to clinical practice and allow for better refinement of the decision aid tool.

An additional group of subjects will review the web-based Sickle Cell Decision Aid. Participants will be asked to navigate the site. As the participant navigates the site, the study interviewer will ask the participants to describe thoughts about the site, including but not limited to ease of navigation, content and construction. Testing may be performed in-person or via telephone. Using qualitative data collection methods, questions will be analyzed allowing for increased focus of questions based on common themes and issues identified during ongoing analysis.

This study will provide information for the conduct of a randomized controlled trial for the use of a web based decision aid to give patients with sickle cell disease and parent/legal guardian of children with sickle cell disease accurate information about risks and benefits of therapies and enable them to make decisions based on their individual values and preferences.

• Study Type: Interventional
• Study Phase: Not Applicable
• Study Design: Allocation: Non-Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Health Services Research
• Condition: Sickle Cell Disease

Intervention

• Other: Qualitative Interviews Decisional Needs Assessment
  Subjects will participate in an open-ended interview regarding type of sickle cell disease, complications, current treatment, and experiences with decision making and sickle cell treatment. Participants will be asked to describe what is important when making health care decisions. Treatment options (hydroxyurea, chronic or monthly blood transfusions, and bone marrow transplantation) will be discussed as well as how a web-based decision aid tool should be developed. The interview will be audio recorded and will take 45 to 60 minutes to complete.
• Other: Sickle Cell Decision Aid
  Participants will be asked to navigate the Sickle Cell Decision Aid site that provides information about risks and benefits of therapies. As the participant navigates the site, the interviewer will ask the participants to describe thoughts about the site, including but not limited to ease of navigation, content and construction. Testing may be performed in-person or via telephone. Interviews will be audio recorded and take up to 60 to 90 minutes to complete.

Study Arms

• Decisional Needs Assessment
  Caregivers and patients with sickle cell disease will participate in a semi-structured open ended interview regarding treatment decision making.
  Intervention: Other: Qualitative Interviews Decisional Needs Assessment
• Beta Testing
  Caregivers and patients with sickle cell disease will review the web-based Sickle Cell Decision Aid.
  Intervention: Other: Sickle Cell Decision Aid

• Publications *: Krishnamurti L, Ross D, Sinha C, Leong T, Bakshi N, Mittal N, Veludhandi D, Pham AP, Taneja A, Gupta K, Nwanze J, Matthews AM, Joshi S, Vazquez Olivieri V, Arjunan S, Okonkwo I, Lukombo I, Lane P, Bakshi N, Loewenstein G. Comparative Effectiveness of a Web-Based Patient Decision Aid for Therapeutic Options for Sickle Cell Disease: Randomized Controlled Trial. J Med Internet Res. 2019 Dec 4;21(12):e14462. doi: 10.2196/14462.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: July 18, 2017): 222
• Original Actual Enrollment: Same as current
• Actual Study Completion Date: March 31, 2015
• Actual Primary Completion Date: March 31, 2015 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

-Individual diagnosed with sickle cell disease (SCD) or parent/legal guardian/caregiver of individual (of any age) diagnosed with SCD

Exclusion Criteria:

There are no exclusions to study participation.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 8 Years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Not Provided

Administrative Information

• NCT Number: NCT03224429
• Other Study ID Numbers: IRB00076096
• Has Data Monitoring Committee: No

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

• IPD Sharing Statement: Not Provided
• Current Responsible Party: Lakshmanan Krishnamurti, Emory University
• Original Responsible Party: Same as current
• Current Study Sponsor: Emory University
• Original Study Sponsor: Same as current
• Collaborators: Patient-Centered Outcomes Research Institute

Investigators

• Principal Investigator: Lakshmanan Krishnamurti, MD; Emory University

• PRS Account: Emory University
• Verification Date: June 2018